Cases: Healthcare suppliers

cancer
A large international pharmaceutical company will apply for the Class 1 reimbursement of a novel therapy, CAR-T, to treat patients with diffuse large B-cell lymphoma (DLBCL). The customer has asked...
CAR T-cell therapy
A large international pharmaceutical company will apply for the Class 1 reimbursement of a novel therapy, CAR-T, to treat patients with paediatric acute lymphoblastic leukaemia (pALL).  The...
Patiënt blood management in België
Patient blood management (PBM) becomes increasingly important for hospitals, as policies and guidelines are developed. The European Commission recently published a practical implementation guide for...
Novartis Logo
Novartis, a large international pharmaceutical company applied for the Class 1 reimbursement of the new drug, Rydapt, to treat patients with acute myeloid leukaemia who are FLT3 mutation-positive....
Default Image - Pharma
Performing a health-economic evaluation (budget impact analysis) of a proposed adaptation of the reimbursement criteria for certain implants in Belgium.
Novartis logo
Novartis, a large international pharmaceutical company had applied for Class 1 reimbursement of Jakavi for adult patients with myelofibrosis.  The company asked hict for support...
Orion Logo
Orion  Orion is a Finnish, Espoo–based pharmaceutical company with branches across Europe. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical...
Logo BD
BD is a medical technology company that serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. BD wants to investigate the market interest...
Qualitative market research: Clinical Practice DVT & PE in 10 Belgian hospitals
This market research was performed to support a pharmaceutical company in the launch of 2 new indications for Product X (New Oral Anticoagulant): acute treatment and prevention of DVT (Deep vein...
Ezelstraat 69 | B- 8000 Brugge | Belgium | Phone: +32.50.33.33.40 | Fax: +32.50.33.33.39 | BTW BE 0866 039 556 | RPR/RPM Brugge | e-mail: info@hict.com